|
Match
|
Document |
Document Title |
|
|
US20090304689 |
METHODS FOR THE IDENTIFICATION OF POLYPEPTIDE ANTIGENS ASSOCIATED WITH DISORDERS INVOLVING ABERRANT CELL PROLIFERATION AND COMPOSITIONS USEFUL FOR THE TREATMENT OF SUCH DISORDERS
Methods and compositions for the development of effective cancer therapies using mitotic inhibitors which have limited general toxicity to normal, non-cancerous cells and tissues are provided. The...
|
|
|
US20090274620 |
Hybridoma Cell Line G250 and its use for Producing Monoclonal Antibodies
This invention relates to a hybridoma cell line which is capable of producing the monoclonal antibody G250. Furthermore, the invention describes the method of employing such cell line for the...
|
|
|
US20090246206 |
BISPECIFIC BINDING AGENTS FOR MODULATING BIOLOGICAL ACTIVITY
Methods for improving the specific binding ability of bispecific binding compositions are described. The bispecific binding compositions are able to target cells by a high affinity targeting domain...
|
|
|
US20090208411 |
Cytotoxicity mediation of cells evidencing surface expression of CD44
This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease...
|
|
|
US20090202559 |
Anti-Mesothelin Antibodies
This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity...
|
|
|
US20090202560 |
Method for diagnosing efficacy of xenotypic antibody therapy
The invention concerns methods and compositions for intiating and/or enhancing an immune response by contacting a binding reagent with a soluble antigen, wherein the binding reagent-antigen pair...
|
|
|
US20090205056 |
METHOD OF SCREENING FOR MODULATORS OF MAP3K11 IN LIVER CANCER CELLS
Detection of expression of the provided protein kinase in cancers is useful as a diagnostic, for determining the effectiveness of drugs, and determining patient prognosis. The encoded polypeptides...
|
|
|
US20090130101 |
ANTI-CANCER THERAPY WITH AN EXTRACT OF SCUTELLARIA BARBATA
Methods of treating cancer with a combination of an extract of Scutellaria barbata D. Don and at least one additional anticancer chemotherapeutic agent are provided. Also provided are kits...
|
|
|
US20090117034 |
Microorganisms for imaging and/or treatment of tumors
Modified viruses encoding transporter proteins and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses also can be used in...
|
|
|
US20090074789 |
COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND CONDITIONS
The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, particularly ocular diseases and conditions, characterized by aberrant...
|
|
|
US20090068144 |
TETRAHYDRO-ISOQUINOLIN-1-ONES FOR THE TREATMENT OF CANCER
The present invention provides a compound selected from compounds of formula I as ligand binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility...
|
|
|
US20090068141 |
AUTOLOGOUS NATURAL KILLER CELLS AND LYMPHODEPLETING CHEMOTHERAPY FOR THE TREATMENT OF CANCER
The invention provides a simple, cost-effective method of preparing a composition comprising natural killer (NK) cells useful for administering to a human. The method comprises (i) depleting CD3 + ...
|
|
|
US20090060913 |
COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES
The present invention is directed to a combination therapy involving a type I anti-CD20 antibody and a type II anti-CD20 antibody for the treatment of a patient suffering from cancer, particularly...
|
|
|
US20090004201 |
Therapy-Enhancing Glucan
A therapeutic composition for treatment of cancer in a mammal is disclosed. The composition comprises an effective amount of a yeast beta-glucan composition which is suitable for oral...
|
|
|
US20080317667 |
Compositions and methods for inhibiting growth of smad4-deficient cancers
The present invention is in the fields of cell biology, immunology and oncology. The invention relates to the discovery that there is a relationship between the expression levels of the tumor...
|
|
|
US20080311126 |
Antisense Oligonucleotides Directed to Ribonucleotide Reducatase R2 and Uses Thereof in Combination Therapies for the Treatment of Cancer
Combination products comprising an antisense oligonucleotide against the gene encoding a mammalian ribonucleotide reductase R2 protein and one or more immunotherapeutic agents, such as cytokines,...
|
|
|
US20080311127 |
Combination therapy for treating disease
Disclosed are methods for treating cancer comprising administering a xenotypic antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a...
|
|
|
US20080286284 |
Compositions of PSMA antibodies
The invention includes antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracellular domain of PSMA, compositions containing one or a...
|
|
|
US20080247990 |
GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES
The invention provides a natural killer cell, NK-92, modified to express a CD16 receptor or an inhibitory killer cell immunoglobulin-like receptor (KIR) on a surface of the cell. In examples, the...
|
|
|
US20080219977 |
Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
The invention relates to a method of treating a warm-blooded animal having pancreatic cancer, in particular it relates
to a method comprising administering to the warm-blooded animal having...
|
|
|
US20080219919 |
Cytotoxicity mediation of cells evidencing surface expression of CD44
This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and...
|
|
|
US20080219997 |
Her-2 binding antagonists
There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from...
|
|
|
US20080206258 |
Novel Tetrahydropyridothiophenes
Compounds of a certain formula (I)
in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.
|
|
|
US20080171051 |
Cancer Treatment
The invention relates to methods and compositions for treatment of cancer. In one embodiment the method involves the use of a c-FLIP inhibitor as the sole active agent. In another embodiment the...
|
|
|
US20080160031 |
Method and Composition for Treatment of Neoplasms
The invention relates to methods of treating a neoplasm in an animal, in particular treating a neoplasm in a human, through the use of isolated nucleic acid sequence, including synthetic viral RNA...
|
|
|
US20080131443 |
Method and composition for reconforming multi-epitopic antigens to intiate an immune response
The invention concerns methods and compositions for initiating and/or enhancing an immune response by contacting a binding reagent with a soluble antigen, wherein the binding reagent-antigen pair...
|
|
|
US20080131365 |
Cancerous disease modifying antibodies
The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell...
|
|
|
US20080118518 |
Cancer stem cell-targeted cancer therapy
The present invention provides methods for stabilizing, reducing or eliminating cancer cells. In particular, the present invention provides prophylactically and/or therapeutically effective...
|
|
|
US20080112960 |
MN/CA IX and EGFR Pathway Inhibition
The invention is based upon the discovery that the EGFR pathway can stimulate a previously unknown tumorigenic function of CA IX, via phosphorylation of the sole tyrosine residue present in CA IX's...
|
|
|
US20080112961 |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies),...
|
|
|
US20080095785 |
MONOCLONAL ANTIBODIES TO HUMAN HIGH MOLECULAR WEIGHT-MELANOMA ASSOCIATED ANTIGEN
The present invention provides monoclonal antibodies that react against high molecular weight melanoma-associated antigen. These antibodies may be used for diagnostic and/or therapeutic purposes.
|
|
|
US20080089895 |
Use of T-cell immune response cDNA 7 (TIRC7) in angiogenic and anti-angiogenic therapy
A novel use of T-cell immune response cDNA 7 (TIRC7) in angiogenic and anti-vided angiogenic therapy is described. Provided are agents such as anti-TIRC7 antibodies and methods of treatment which...
|
|
|
US20080089893 |
THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELLED ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR TREATMENT OF B CELL LYMPHOMA
Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of...
|
|
|
US20080050390 |
Administration of gamma globulins to treat metastatic melanoma
This invention relates to cancer therapy and in particular to the administration of gamma globulins to inhibit both primary tumor and metastasis and augment treatment of primary cancerous tumors....
|
|
|
US20080038189 |
RNA interference mediated inhibition of aurorakinase B and its combinations as anticancer therapy
This invention relates to the use of short nucleic acid molecules that modulate Aurora-B kinase (AurkB) expression. The invention includes compounds, compositions and methods useful for the...
|
|
|
US20080038260 |
ILT3 binding molecules and uses therefor
The present invention provides binding molecules that specifically bind to ILT3, e.g., human ILT3 (hILT3), on antigen presenting cells, such as for example, monocytes, macrophages and dendritic...
|
|
|
US20080025989 |
ANTI-CD70 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS
Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the...
|
|
|
US20080026047 |
Cancer Detection Reagents And Uses In Pathology And Diagnostics And Cancer Cell Death
Cancer detection reagents have been identified through comparison of cancer mRNAs with the transcriptome of healthy cells. These cancer detection reagents may be used for a variety of purposes...
|
|
|
US20080020011 |
THERAPEUTIC IMPLANT
The invention relates an implant, which comprises a biologically compatible substrate, to which at least one moiety is bound by a ligand, the moiety being one which specifically binds to and...
|